| Summary: | Background Up to 50% of renal transplant recipients can experience diabetes mellitus (DM) and insulin resistance (IR). Both metabolic complications significantly increase the risk of progressive loss of renal function, cardiovascular morbidity, and death. On the contrary, the current body of evidence shows that changes in adiponectin, a cytokine of adipose tissue, is significantly associated with the development of DM and other components of metabolic syndrome. In the present study, the authors aimed to characterize the association between post-transplantation changes in adiponectin level and both IR and new-onset diabetes mellitus (NODM).
Patients and methods The authors recruited 30 patients who received a living-donor kidney at least 6 months before study’s enrollment. Most patients were males (70%), with age ranged from 25 to 55 years. The following data were collected before the transplantation and at the end of follow-up: blood glucose profile, glycated hemoglobin, serum insulin, homeostasis model assessment-insulin resistance (HOMA-IR), lipid profile, and serum adiponectin.
Results Six months after the transplantation, seven (23.3%) patients developed NODM. There was a negative correlation between serum adiponectin and HOMA-IR before and after kidney transplantation. Low adiponectin levels before and after transplantation was associated with a greater incidence of new onset diabetes after transplantation (NODAT). Patients who developed NODAT had lower levels of adiponectin compared with patients who did not develop NODAT before and after transplantation.
Conclusion Low adiponectin level is associated with increased risk of NODM in renal transplant recipients. In addition, there is a negative correlation between serum adiponectin and IR before and after kidney transplantation.
|
|---|
